Matches in UGent Biblio for { <https://biblio.ugent.be/publication/4208913#aggregation> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B571188.
- aggregation creator B571189.
- aggregation creator B571190.
- aggregation creator B571191.
- aggregation creator B571192.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 4208913.bibtex.
- aggregation hasFormat 4208913.csv.
- aggregation hasFormat 4208913.dc.
- aggregation hasFormat 4208913.didl.
- aggregation hasFormat 4208913.doc.
- aggregation hasFormat 4208913.json.
- aggregation hasFormat 4208913.mets.
- aggregation hasFormat 4208913.mods.
- aggregation hasFormat 4208913.rdf.
- aggregation hasFormat 4208913.ris.
- aggregation hasFormat 4208913.txt.
- aggregation hasFormat 4208913.xls.
- aggregation hasFormat 4208913.yaml.
- aggregation isPartOf urn:issn:0315-162X.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis".
- aggregation abstract "Objective. Systemic sclerosis (SSc) is characterized by microvascular injury, fibrosis, and hypoxia of involved tissues. The vasoactive peptide endothelin-1 (ET-1) seems to be implicated in these events. Using nailfold videocapillaroscopy (NYC), we evaluated longterm effects of ET-1 antagonist treatment on nailfold microvascular damage in patients with SSc, over a 3-year followup period. Methods. Thirty patients with SSc (mean age 64 +/- 5 yrs, mean disease duration 8 +/- 1 yrs) were recruited during their programmed standard treatment protocols. At baseline (TO), 15 patients with SSc (mean age 63 +/- 15 yrs, mean disease duration 7 +/- 3 yrs), already receiving cyclic intravenous infusion of iloprost (5 continuous days, average 80 mu g/day, every 3 mo), continued the treatment for a further 3 years (ILO group). The remaining 15 patients with SSc (mean age 68 +/- 13 yrs, mean disease duration 8 +/- 4 yrs), although they continued the same cyclic intravenous iloprost treatment as the previous group, also received bosentan 125 mg twice a day for 3 years (ILO+BOS group). Qualitative analysis (scleroderma patterns) and semiquantitative scoring of the microvascular damage were performed by validated routine NYC methods. Results. During followup, a statistically significant increase of capillary number was observed in the ILO+BOS group (p < 0.02), with a significant and progressive increase of angiogenesis (p < 0.01). In contrast, the ILO group showed a statistically significant decrease of capillary number (p < 0.05). After 3 years the number of capillaries was significantly higher in the ILO+BOS group than in the ILO group (p < 0.05). The score for giant capillaries decreased significantly in both groups of patients with SSc (p < 0.05). Conclusion. In this open study, longterm treatment with ET-1 receptor antagonist in combination with iloprost was found to interfere with progression of nailfold microvascular damage in patients with SSc, as assessed by NYC over a 3-year followup period.".
- aggregation authorList BK921486.
- aggregation endPage "45".
- aggregation issue "1".
- aggregation startPage "40".
- aggregation volume "40".
- aggregation aggregates 4208921.
- aggregation isDescribedBy 4208913.
- aggregation similarTo jrheum.120416.
- aggregation similarTo LU-4208913.